Companies Cryptocurrencies
Gilead Sciences Inc
Gilead Sciences Inc
Exchange: Nasdaq Global Select
IPO Date: 01/01/1992
CEO: Mr. Daniel O'Day
Drug Manufacturers General Healthcare 🔗
  • GILD
  • 62.86
  • 78786838528
    market cap
  • -0.90999985
If you bought

shares of Gilead Sciences Inc (GILD) on
You would have made
Old Price $12 Current Price $12

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 11,000 full-time employees. The firm’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. The company offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The company had operations in more than 30 countries, as of December 31, 2016.

Address: 333 LAKESIDE DR Foster City CALIFORNIA 94404

Stay updated.